Citi has maintained a 'buy' rating on AstraZeneca ahead of its Q2 earnings report due July 27, forecasting an 11% rise in earnings per share at constant exchange rates. The broker highlights upcoming phase three trial results for key drugs like Wainua, Datroway, and camizestrant in the second half of the year as major growth drivers. Citi sees a favorable risk-reward balance, with potential upside of around 40% if trial data is positive, and notes additional upside from pipeline drugs tozorakimab and efzimfotase alfa. Investors will focus on these trial readouts and the company's guidance during the results call.
New research from Spherix Global Insights reveals that despite advances in lupus treatment, including increased use of biologics and new therapies, many patients with systemic lupus erythematosus (SLE) continue to experience persistent symptoms, freq...
The FTSE 100 fell 40 points to 10,639, with mixed sector performance as airlines and defence stocks gained while others like Primark owner AB Foods declined. Microsoft announced cutting 4,800 jobs to focus on growth priorities, causing a 1.7% drop in...
The FTSE 100 fell 26 points to 10,653 amid declines in major stocks like AstraZeneca and Rolls-Royce, while easyJet and ITV saw gains due to takeover and sale deals. UK banks anticipate eased capital requirements from the Bank of England, potentially...
The global AI in Pathology market, valued at $28.75 million in 2025, is projected to grow at a 9.12% CAGR to reach $68.81 million by 2035. Growth is driven by rising demand for digital pathology, AI diagnostics, and improved workflow efficiency throu...
